The pathogenic role of tissue-resident immune cells in psoriasis

Trends in Immunology

Volumn 28, Issue 2, 2007, Pages 51-57

  Boyman, Onur ^a   Conrad, Curdin ^b   Tonel, Giulia ^b   Gilliet, Michel ^c   Nestle, Frank O ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD11; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ARTICLE; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; NONHUMAN; PSORIASIS; T LYMPHOCYTE;

ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; PSORIASIS;

EID: 33846616821     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2006.12.005     Document Type: Article

References (80)

1. Griffiths C.E., and Voorhees J.J. Psoriasis, T cells and autoimmunity. J. R. Soc. Med. 89 (1996) 315-319
2. Valdimarsson H., et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunol. Today 16 (1995) 145-149
3. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113 (2004) 1664-1675
4. Prinz J.C. Disease mimicry - a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry?. Autoimmun. Rev. 3 (2004) 10-15
5. Gudjonsson J.E., et al. Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135 (2004) 1-8
6. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46 (2002) 1-23
7. Schon M.P., and Boehncke W.H. Psoriasis. New Engl. J. Med. 352 (2005) 1899-1912
8. Allen M.H., et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J. Invest. Dermatol. 124 (2005) 103-106
9. Nair R.P., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. 78 (2006) 827-851
10. Weinstein G.D. Methotrexate. Ann. Intern. Med. 86 (1977) 199-204
11. Ellis C.N., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256 (1986) 3110-3116
12. Weinshenker B.G., et al. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J. Am. Acad. Dermatol. 20 (1989) 1132-1133
13. Bachelez H., et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11 (1998) 53-62
14. Gottlieb S.L., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1 (1995) 442-447
15. Krueger G.G., and Ellis C.N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol. 148 (2003) 784-788
16. Prinz J.C., et al. Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur. J. Immunol. 29 (1999) 3360-3368
17. + T cells induces psoriasis. Am. J. Pathol. 155 (1999) 145-158
18. Boyman O., et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. 199 (2004) 731-736
19. Sano S., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11 (2005) 43-49
20. Austin L.M., et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113 (1999) 752-759
21. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174 (2005) 164-173
22. Nickoloff B.J. Skin innate immune system in psoriasis: friend or foe?. J. Clin. Invest. 104 (1999) 1161-1164
23. Bos J.D., et al. Psoriasis: dysregulation of innate immunity. Br. J. Dermatol. 152 (2005) 1098-1107
24. Gaspari A.A. Innate and adaptive immunity and the pathophysiology of psoriasis. J. Am. Acad. Dermatol. 54 3, Suppl. 2 (2006) S67-S80
25. Nestle F.O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202 (2005) 135-143
26. Mease P.J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
27. Chaudhari U., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
28. Reich K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
29. Nestle F.O., and Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123 (2004) xiv-xv
30. Kauffman C.L., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123 (2004) 1037-1044
31. Teunissen M.B., et al. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111 (1998) 645-649
32. Rich B.E., and Kupper T.S. Cytokines: IL-20 - a new effector in skin inflammation. Curr. Biol. 11 (2001) R531-R534
33. + myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. 126 (2006) 1590-1599
34. Wolk K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36 (2006) 1309-1323
35. Lee E., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199 (2004) 125-130
36. Chan J.R., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203 (2006) 2577-2587
37. Nestle F.O., et al. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94 (1994) 202-209
38. Lowes M.A., et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19057-19062
39. Cumberbatch M., et al. Impaired Langerhans cell migration in psoriasis. J. Exp. Med. 203 (2006) 953-960
40. Stratis A., et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Invest. 116 (2006) 2094-2104
41. Wang H., et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J. Clin. Invest. 116 (2006) 2105-2114
42. Clark R.A., and Kupper T.S. Misbehaving macrophages in the pathogenesis of psoriasis. J. Clin. Invest. 116 (2006) 2084-2087
43. Zenz R., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
44. Schroder J.M., and Harder J. Antimicrobial skin peptides and proteins. Cell. Mol. Life Sci. 63 (2006) 469-486
45. McInturff J.E., et al. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J. Invest. Dermatol. 125 (2005) 1-8
46. Albanesi C., et al. Keratinocytes in inflammatory skin diseases. Curr. Drug Targets Inflamm. Allergy 4 (2005) 329-334
47. Clark R.A., et al. Human skin cells support thymus-independent T cell development. J. Clin. Invest. 115 (2005) 3239-3249
48. Streilein J.W. Skin-associated lymphoid tissues (SALT): origins and functions. J. Invest. Dermatol. 80 Suppl. (1983) 12s-16s
49. Bos J.D., et al. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J. Invest. Dermatol. 88 (1987) 569-573
50. Robert C., and Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. New Engl. J. Med. 341 (1999) 1817-1828
51. Luster A.D., et al. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6 (2005) 1182-1190
52. Kupper T.S., and Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4 (2004) 211-222
53. Homey B. Chemokines and inflammatory skin diseases. Adv. Dermatol. 21 (2005) 251-277
54. + T cells are resident in normal skin. J. Immunol. 176 (2006) 4431-4439
55. Nestle F.O., et al. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151 (1993) 6535-6545
56. Pennington D.J., et al. γδ T cell development - having the strength to get there. Curr. Opin. Immunol. 17 (2005) 108-115
57. Curry J.L., et al. Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch. Pathol. Lab. Med. 127 (2003) 289-296
58. +) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 150 (2004) 852-859
59. Wrone-Smith T., and Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98 (1996) 1878-1887
60. Boyman O., et al. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br. J. Dermatol. 152 (2005) 1211-1218
61. Kohrgruber N., et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol. 173 (2004) 6592-6602
62. Weninger W., et al. Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J. Immunol. 170 (2003) 4638-4648
63. Lew W., et al. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression. Trends Immunol. 25 (2004) 295-305
64. Bhushan M., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. 146 (2002) 824-831
65. Friedrich M., et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. 297 (2006) 345-351
66. Westermann J., et al. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann. Intern. Med. 135 (2001) 279-295
67. von Bonin A., et al. Efomycine M: an inhibitor of selectins?. Nat. Med. 12 (2006) 873-874
68. Kanamori H., et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am. J. Hematol. 71 (2002) 41-44
69. Smith C.H., and Barker J.N. Psoriasis and its management. BMJ 333 (2006) 380-384
70. Feldmann M., and Maini R.N. Anti-TNFα therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
71. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3 (2003) 521-533
72. Smolen J.S., et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin. Rev. Allergy Immunol. 28 (2005) 239-248
73. Mannon P.J., et al. Anti-interleukin-12 antibody for active Crohn's disease. New Engl. J. Med. 351 (2004) 2069-2079
74. Boyman O., et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311 (2006) 1924-1927
75. Kary S., et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann. Rheum. Dis. 65 (2006) 405-407
76. Lebwohl M., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New Engl. J. Med. 349 (2003) 2004-2013
77. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New Engl. J. Med. 345 (2001) 248-255
78. Surh C.D., et al. Homeostasis of memory T cells. Immunol. Rev. 211 (2006) 154-163
79. + cells. J. Exp. Med. 203 (2006) 1817-1825
80. Wherry E.J., et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16004-16009